S-Adenosylmethionine Affects ERK1/2 and Stat3 Pathways and Induces Apotosis in Osteosarcoma Cells

Journal of Cellular Physiology

Volumn 231, Issue 2, 2016, Pages 428-435

  Ilisso, Concetta Paola ^a   Sapio, Luigi ^a   Delle Cave, Donatella ^a   Illiano, Michela ^a   Spina, Annamaria ^a   Cacciapuoti, Giovanna ^a   Naviglio, Silvio ^a   Porcelli, Marina ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; S ADENOSYLMETHIONINE; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; STAT3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MTT ASSAY; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; U2OS CELL LINE; BONE NEOPLASMS; CELL CYCLE CHECKPOINT; DRUG EFFECTS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MAP KINASE SIGNALING SYSTEM; OSTEOSARCOMA; PHOSPHORYLATION; S-ADENOSYLMETHIONINE; STAT3 TRANSCRIPTION FACTOR;

EID: 84944930891     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25089     Document Type: Article

References (76)

1. Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA. 2010. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 9:1781-1791.
2. Ansorena E, García-Trevijano ER, Martínez-Chantar ML, Huang ZZ, Chen L, Mato JM, Iraburu M, Lu SC, Avila MA. 2002. S-Adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells. Hepatology 35:274-280.
3. Anstee QM, Day CP. 2012. S-Adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility. J Hepatol 57:1097-1109.
4. Bird AP. 1986. CpG-rich islands and the function of DNA methylation. Nature 321:209-213.
5. Bottiglieri T. 2002. S-Adenosyl-L-methionine (SAMe): From the bench to the bedside-molecular basis of a pleiotropic molecule. Am J Clin Nutr 76:1151S-1157S.
6. Bradford MM. 1976. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Cai Y, Cai T, Chen Y. 2014. Wnt pathway in osteosarcoma, from oncogenic to therapeutic. J Cell Biochem 115:625-631.
8. Cantoni GL. 1953. S-Adenosylmethionine, a new intermediate formed enzimatically from L-metionine and adenosinetriphosphate. J Biol Chem 204:403-416.
9. Cantoni GL. 1975. Biological methylation: Selected aspects. Annu Rev Biochem 44:435-451.
10. Chen H, Xia M, Lin M, Yang H, Kuhlenkamp J, Li T, Sodir NM, Chen YH, Josef-Lenz H, Laird PW, Clarke S, Mato JM, Lu SC. 2007. Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells. Gastroenterology 133:207-218.
11. Chen L, Wang Q, Wang GD, Wang HS, Huang Y, Liu XM, Cai XH. 2013. MiR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma. FEBS Lett 587:1366-1372.
12. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP. 1996. S-Adenosylmethionine and methylation. FASEB J 10:471-480.
13. Chik F, Machnes Z, Szyf M. 2014. Synergistic anti-breast cancer effect of combined treatment with the methyl donor S-adenosylmethionine amd the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Carcinogenesis 35:138-144.
14. Choy E. 2014. Osteosarcoma: Symptoms, diagnosis and treatment options. 978-1-63321-057-8_eBook.
15. Cragg GM, Grothaus PG, Newman DJ. 2014. New horizons for old drugs and drug leads. J Nat Prod 77:703-723.
16. Da MX, Zhang YB, Yao JB, Duan YX. 2014. DNA methylation regulates expression of VEGF-C, and S-adenosylmethionine is effective for VEGF-C methylation and for inhibiting cancer growth. Braz J Med Biol Res 47:1021-1028.
17. Dawson VL, Dawson TM. 2004. Deadly conversations: Nuclear-mitochondrial cross-talk. J Bioenerg Biomembr 36:287-294.
18. Finbloom DS, Larner AC. 1995. Regulation of the Jak/STAT signalling pathway. Cell Signal 7:739-745.
19. Fontecave M, Atta M, Mulliez E. 2004. S-Adenosylmethionine: Nothing goes to waste. Trends Biochem Sci 29:243-249.
20. Fossey SL, Bear MD, Lin J, Li C, Schwartz EB, Li PK, Fuchs JR, Fenger J, Kisseberth WC, London CA. 2011. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer 11:112.
21. Frey PA, Hegeman AD, Ruzicka FJ. 2008. The radical SAM superfamily. Crit Rev Biochem Mol Biol 43:63-88.
22. Gérard C, Goldbeter A. 2014. The balance between cell cycle arrest and cell proliferation: Control by the extracellular matrix and by contact inhibition. Interface Focus 4:20130075.
23. Germain D, Frank DA. 2007. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 13:5665-5669.
24. Gomez-Santos L, Vazquez-Chantada M, Mato JM, Martinez-Chantar ML. 2012. SAMe and HuR in liver physiology: Usefulness of stem cells in hepatic differentiation research. Methods Mol Biol 826:133-149.
25. Hussian Z, Khan MI, Shahid M, Almajhdi FN. 2013. S-Adenosylmethionine, a methyl donor, up regulates tissue inhibitor of metalloproteinase-2 in colorectal cancer. Genet Mol Res 12:1106-1118.
26. Ilisso CP, Castellano M, Zappavigna S, Lombardi A, Vitale G, Dicitore A, Cacciapuoti G, Caraglia M, Porcelli M. 2015. The methyl donor S-adenosylmethionine potentiates doxorubicin effects on apoptosis of hormone-dependent breast cancer cell lines. Endocrine [Epub ahead of print] DOI: 10.1007/s12020-014-0484-7.
27. Johnston PA, Grandis JR. 2011. STAT3 signaling: Anticancer strategies and challenges. Mol Interv 11:18-26.
28. Kotb M, Geller AM. 1993. Methionine adenosyltransferase: Structure and function. Pharmacol Ther 59:125-143.
29. Kreis NN, Sanhaji M, Rieger MA, Louwen F, Yuan J. 2014. P21Waf1/Cip1 deficiency causes multiple mitotic defects in tumor cells. Oncogene 33:5716-5728.
30. Li TWH, Peng H, Yang H, Kurniawidjaja S, Panthaki P, Zheng Y, Mato JM, Lu SC. 2015. S-adenosylmethionine and methylthioadenosine inhibit beta catenin signaling by multiple mechanisms in liver and colon cancer. Mol Pharmacol 87:77-86.
31. Li TW, Yang H, Peng H, Xia M, Mato JM, Lu SC. 2012. Effects of S-adenosylmethionine and metylthioadenosine on inflammation-induced colon cancer in mice. Carcinogenesis 33:427-435.
32. Li TW, Zhang Q, Oh P, Xia M, Chen H, Bemanian S, Lastra N, Circ M, Moyer MP, Mato JM, Aw TY, Lu SC. 2009. S-Adenosylmethionine and methylthioadenosine inhibit cellular FLICE inhibitory protein expression and induce apoptosis in colon cancer cells. Mol Pharmacol 76:192-200.
33. Lu SC. 2000. S-Adenosylmethionine. Int J Biochem Cell Biol 32:391-395.
34. Lu SC. 2009. Regulation of glutathione synthesis. Mol Aspects Med 30:42-59.
35. Lu SC, Mato JM. 2005. Role of methionine adenosyltrasferase and S-adenosylmethionine in alcohol-associated liver cancer. Alcohol 35:227-234.
36. Lu SC, Mato JM. 2012. S-Adenosylmethionine in liver health, injury, and cancer. Physiol Rev 92:1515-1542.
37. Lucero CM, Vega OA, Osorio MM, Tapia JC, Antonelli M, Stein GS, van Wijnen AJ, Galindo MA. 2013. The cancer-related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines. J Cell Physiol 228:714-723.
38. Luo J, Li YN, Wang F, Zhang WM, Geng X. 2010. S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer. Int J Biol Sci 6:784-795.
39. Markham GD, Pajares MA. 2009. Structure-function relationships in methionine adenosyltransferases. Cell Mol Life Sci 66:636-648.
40. Martinez-Lopez N, Valera-Rey M, Ariz U, Embade N, Vazquez-Chantada M, Fernandez-Ramos D, Gomez-Santos L, Lu SC, Martinez-Chantar ML. 2008. S-Adenosylmethionine and proliferation: New pathways, new targets. Biochem Soc Trans 36:848-852.
41. Mato JM, Alvarez L, Ortiz P, Pajares MA. 1997. S-Adenosylmethionine synthesis: Molecular mechanisms and clinical implications. Pharmacol Ther 73:265-280.
42. Mato JM, Corrales FJ, Lu SC, Avila MA. 2002. S-Adenosylmethionine: A control switch that regulates liver function. FASEB J 16:15-26.
43. Mato JM, Martinez-Chantar ML, Lu SC. 2013. S-Adenosylmethionine metabolism and liver disease. Ann Hepatol 12:183-189.
44. Morana A, Stiuso P, Colonna G, Lamberti M, Cartenì M, De Rosa M. 2002. Stabilization of S-adenosyl-L-methionine promoted by trehalose. Biochim Biophys Acta 1573:105-108.
45. Naviglio S, Mattecucci C, Matoskova B, Nagase T, Nomura N, Di Fiore PP, Draetta GF. 1998. UBPY: A growth-regulated human ubiquitin isopeptidase. EMBO J 17:3241-3250.
46. Naviglio S. 2013. The possible use of inorganic phosphate in osteosarcoma therapy. Future Oncol 9:1249-1251.
47. Nishikawa K, Iwamoto Y, Kobayashi Y, Katsuoka F, Kawaguchi S, Tsujita T, Nakamura T, Kato S, Yamamoto M, Takayanagi H, Ishii M. 2014. DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S-adenosylmethionine-producing metabolic pathway. Nat Med 21:281-287.
48. Pajares MA, Markham GD. 2011. Methionine adenosyltransferase (S-adenosylmethionine synthetase). Adv Enzymol Relat Areas Mol Biol 78:449-451.
49. Pakneshan P, Szyf M, Farias-Eisner R, Rabbani SA. 2004. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem 279:31735-31744.
50. Papakostas GI, Cassiello CF, Iovieno N. 2012. Folates and S-adenosylmethionine for major depressive disorder. Can J Psychiatry 57:406-413.
51. Parashar S, Cheishvili D, Arakelian A, Hussain Z, Tanvir I, Khan HA, Szyf M, Rabbani SA. 2015. S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: Therapeutic and diagnostic clinical applications. Cancer Med 4:732-734.
52. Pegg AE. 1986. Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 234:249-262.
53. Pignochino Y, Grignani G, Cavalloni G, Motta M, Tapparo M, Bruno S, Bottos A, Gammaitoni L, Migliardi G, Camussi G, Alberghini M, Torchio B, Ferrari S, Bussolino F, Fagioli F, Picci P, Aglietta M. 2009. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 8:118.
54. Porcelli M, Cacciapuoti G, Cartenì-Farina M, Gambacorta A. 1988. S-Adenosylmethionine synthetase in the thermophilic archaebacterium Sulfolobus solfataricus. Purification and characterization of two isoforms. Eur J Biochem 177:273-280.
55. Reytor E, Pérez-Miguelsanz J, Alvarez L, Pèrez-Sala D, Pajares MA. 2009. Conformational signals in the C-terminal domain of methionine adenosyltransferase I/III determine its nucleocytoplasmic distribution. FASEB J 23:3347-3360.
56. Ryu K, Choy E, Yang C, Susa M, Hornicek FJ, Mankin H, Duan Z. 2010. Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. J Orthop Res 28:971-978.
57. Salas S, Jiguet-Jiglaire C, Campion L, Bartoli C, Frassineti F, Deville JL, Maues De Paula A, Forest F, Jézéquel P, Gentet JC, Bouvier C. 2014. Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma. BMC Cancer 14:606.
58. Salvatore F, Borek E, Zappia V, Williams-Ashman HG, Schlenk F. 1977. The biochemistry of adenosylmethionine. New York: Columbia University Press, pp 1-588.
59. Santarpia L, Lippman SM, El-Naggar AK. 2012. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16:103-119.
60. Sauter M, Moffatt B, Saechao MC, Hell R, Wirtz M. 2013. Methionine salvage and S-adenosylmethionine: Essential links between sulfur, ethylene and polyamine biosynthesis. Biochem J 451:145-154.
61. Shukeir N, Pakneshan P, Chen G, Szyf M, Rabbani SA. 2006. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res 66:9202-9210.
62. Shukeir N, Stefanska B, Parashar S, Chik F, Arakelian A, Szyf M, Rabbani SA. 2015. Pharmacological methyl group donors block skeletal metastasis in vitro and in vivo. Br J Pharmacol 172:2769-2781.
63. Si H, Peng C, Li J, Wang X, Zhai L, Li X, Li J. 2012. RNAi-mediated knockdown of ERK1/2 inhibits cell proliferation and invasion and increases chemosensitivity to cisplatin in human osteosarcoma U2-OS cells in vitro. Int J Oncol 40:1291-1297.
64. Soeken KL, Lee WL, Bausell RB, Agelli M, Berman BM. 2002. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Farm Pract 51:425-430.
65. Spina A, Sorvillo L, Di Maiolo F, Esposito A, D'Auria R, Di Gesto D, Chiosi E, Naviglio S. 2013a. Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway. J Cell Physiol 228:198-206.
66. Spina A, Sorvillo L, Esposito A, Borgia A, Sapio L, Naviglio S. 2013b. Inorganic phosphate as a signaling molecule: A potential strategy in osteosarcoma treatment. Curr Pharm Des 19:5394-5403.
67. Struck AW, Thompson ML, Wong LS, Micklefield J. 2012. S-Adenosylmethionine-dependent methyltransferases: highly versatile enzymes in biocatalysis, biosynthesis and other biotechnological applications. Chembiochem 13:2642-2655.
68. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, Purushotham AD, Naredi P, Eggermont A, Brennar MF, Steinberg ML, De Ridder M, McCloskey SA, Verellen D, Roberts T, Storme G, Hicks RJ, Ell PJ, Hirsch BR, Carbone DP, Schulman KA, Catchpole P, Taylor D, Geissler J, Brinker NG, Meltzer D, Kerr D, Aapro M. 2011. Delivering affordable cancer care in high-income countries. Lancet Oncol 12:933-980.
69. Usdin E, Borchardt RT, Creveling CR. 1982. Biochemistry of S-adenosylmethionine and related compounds. London: MacMillan Press, pp 1-760.
70. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. 1995. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184:39-51.
71. Wang X, Goldstein D, Crowe PJ, Yang JL. 2014. Impact of STAT3 inhibition on survival of osteosarcoma cell lines. Anticancer Res 34:6537-6545.
72. Yan J, Wang Q, Zou K, Wang L, Schwartz EB, Fuchs JR, Zheng Z, Wu J. 2015. Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma. Mol Med Rep 12:498-502.
73. Yang H, Sadda MR, Li M, Zeng Y, Chen L, Bae W, Ou X, Runnegar MT, Mato JM, Lu SC. 2004. S-adenosylmethionine and its metabolite induce apoptosis in HepG2 cells: Role of protein phosphatase 1 and Bcl-x(S). Hepatology 40:221-231.
74. Yang J, Zhang W. 2013. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol 25:398-406.
75. Yao W, Wang X, Cai Q, Gao S, Wang J, Zhang P. 2014. TRAF4 enhances osteosarcoma cell proliferation and invasion by Akt signaling pathway. Oncol Res 22:21-28.
76. Yu Y, Luk F, Yang JL, Walsh WR. 2011. Ras/Raf/MEK/ERK pathway is associated with lung metastasis of osteosarcoma in an orthotopic mouse model. Anticancer Res 31:1147-1152.